Nan Fung Trinity HK Ltd. Grows Position in Vaxcyte, Inc. $PCVX

Nan Fung Trinity HK Ltd. grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 37.1% in the 4th quarter, HoldingsChannel reports. The firm owned 142,930 shares of the company’s stock after acquiring an additional 38,680 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Vaxcyte were worth $6,595,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in PCVX. Deep Track Capital LP increased its position in shares of Vaxcyte by 39.5% during the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock valued at $108,060,000 after purchasing an additional 850,000 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Vaxcyte during the 2nd quarter valued at $26,318,000. Westfield Capital Management Co. LP increased its position in shares of Vaxcyte by 21.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 3,732,715 shares of the company’s stock valued at $134,452,000 after purchasing an additional 663,817 shares during the last quarter. State Street Corp increased its position in shares of Vaxcyte by 12.1% during the 2nd quarter. State Street Corp now owns 4,942,235 shares of the company’s stock valued at $160,672,000 after purchasing an additional 534,552 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP increased its position in shares of Vaxcyte by 12.2% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 3,784,755 shares of the company’s stock valued at $136,327,000 after purchasing an additional 411,918 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total value of $180,000.00. Following the completion of the sale, the chief accounting officer owned 28,975 shares of the company’s stock, valued at approximately $1,738,500. This trade represents a 9.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $56.83, for a total value of $127,867.50. Following the completion of the sale, the chief operating officer directly owned 160,744 shares of the company’s stock, valued at approximately $9,135,081.52. This trade represents a 1.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 17,037 shares of company stock valued at $994,899. 3.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on PCVX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. BTIG Research raised their target price on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Guggenheim reaffirmed a “buy” rating and set a $116.00 target price on shares of Vaxcyte in a research report on Monday, February 2nd. Finally, Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Vaxcyte Stock Performance

Shares of PCVX opened at $53.01 on Friday. The business has a 50-day moving average of $58.41 and a 200 day moving average of $51.83. Vaxcyte, Inc. has a fifty-two week low of $28.64 and a fifty-two week high of $65.00. The firm has a market cap of $7.65 billion, a P/E ratio of -7.70 and a beta of 1.30.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the prior year, the firm earned ($1.04) earnings per share. As a group, research analysts predict that Vaxcyte, Inc. will post -7.46 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.